Editor’s note: We at The Rheumatologist are saddened to hear of the passing of Richard Brasington Jr., MD, FACP, MACR. Dr. Brasington leaves a legacy of excellence as an outstanding clinician, educator, scholar and more. One of the many ways that he contributed to our community was as the associate editor of The Rheumatologist between…
A large, international team of rheumatologists, geneticists, hematologists and other researchers has discovered a severe inflammatory syndrome linked to an acquired genetic mutation in the bone marrow of older men. The X-linked syndrome, they found, is caused by a somatic mutation in myeloid stem cells that hobbles the master regulator of a pathway tasked with…
I never wake up late. This wasn’t always the case. All the way through residency, I was completely dependent on alarm clocks to keep from oversleeping. So much so that when my alarm clock broke halfway through my internship, I replaced it the next day. I remember driving in the middle of the night to…
With extensive leadership experience in practice and through many roles with the ACR’s committees, executive board of directors and Rheumatology Research Foundation, Dr. Karp is ready to address workforce shortages, workplace bias and member engagement to ensure a strong future for the College through COVID-19 and beyond.
In 2018, the Rheumatology Research Foundation embarked on its third and most ambitious fundraising campaign, the Leading Boldly: Transforming Rheumatology campaign, with a goal of raising $75 million over five years. The campaign supports Foundation programs to recruit the best and brightest into the field, train rheumatology health professionals at all career stages and support…
Research in The New England Journal of Medicine has opened new avenues for exploring the pathophysiology of disease flares in rheumatoid arthritis.1 Through longitudinal genomic analysis, researchers have identified a naive B cell signature prior to rheumatoid arthritis flares, as well as a type of mesenchymal cell, that may play an important role in flare…
Over 50 years ago, an article appeared in The New England Journal of Medicine: “Immunologic Factors and Clinical Activity in Systemic Lupus Erythematosus.”1 Written by a young postdoctoral fellow, Peter H. Schur, MD, and colleagues, the article synthesized important work in the field at the time. What follows is a discussion of the historical context…
Vaneet K Sandhu, MD, FACR, RhMSUS, discusses how rheumatologists should persevere and collaborate with colleagues to overcome the challenges of the pandemic.
The desire for safety during the COVID-19 pandemic has forced rheumatology fellowship programs to embrace virtual platforms. Here are some insights into how this change has affected recruitment in 2020.
During ACR Convergence 2020 in early November, the ACR and ARP honored a group of distinguished individuals who have made significant contributions to rheumatology research, education and patient care. This month, The Rheumatologist speaks with the winners of the ARP Merit Awards and the ACR’s Distinguished Fellows. In addition, we bring you the first ever…
Christine Stamatos brings a combined focus on advanced education and service to connect and mobilize rheumatology professionals in these challenging times.
ACR CONVERGENCE 2020—At the ACR’s fully virtual annual meeting on Saturday, Nov. 7, Anthony S. Fauci, MD, director of the National Institute of Allergy and Infectious Diseases (NIAID) since 1984, delivered a special lecture on COVID-19, from virology to therapy to vaccine development. Novel Coronavirus, Familiar Vectors When Chinese physicians first reported infections by what…
ACR CONVERGENCE 2020—A scientific session on Sunday, Nov. 8, focused on vaccine prospects in COVID-19. Dan Barouch, MD, PhD, director of the Center for Virology and Vaccine Research at Beth Israel Deaconess Medical Center and the William Bosworth Castle Professor of Medicine at Harvard Medical School in Boston, shared his insights about vaccine development across…
ACR CONVERGENCE 2020—Among the many ways in which the COVID-19 pandemic has changed the face of modern medicine is the emergence of multisystem inflammatory syndrome in children (MIS-C), a rare but serious condition that shares many features of Kawasaki disease (KD). With this topic in mind, leading pediatric experts from around the world came together…
Roberto Caricchio, MD, discusses what trials of repurposed rheumatology drugs to treat COVID-19 cytokine storm have shown so far.
ACR CONVERGENCE 2020—The ACR’s first fully virtual annual meeting kicked off on Thursday, Nov. 5. During the Opening Session, ACR President Ellen M. Gravallese, MD, talked about how the specialty’s response during the pandemic has provided great hope and will help rheumatology become an even more essential specialty. At the first Plenary Session on Friday,…
ACR CONVERGENCE 2020—At the annual meeting’s second Plenary Session, Saturday, Nov. 7, speakers highlighted phase 2 results of a potential new biologic for systemic lupus erythematosus (SLE), as well as data on remission maintenance in rheumatoid arthritis (RA) after withdrawal of etanercept or methotrexate. Phase 2 Trial of Monoclonal Antibody for Lupus (LILAC) Several converging…
ACR CONVERGENCE 2020—Moderated by Bill St.Clair, MD, MACR, an ACR past president and a professor of medicine and immunology at Duke University Medical Center, Durham, N.C., an abstract session on Friday, Nov. 6, focused on the diagnosis, manifestations and outcomes of rheumatoid arthritis (RA), with a focus on interstitial lung disease. RA with ILD Jeffrey…
ACR CONVERGENCE 2020—In many ways, the current plethora of treatment options for rheumatoid arthritis patients represents an embarrassment of riches. However, while many therapeutics approved by the U.S. Food & Drug Administration (FDA) are available, knowing the order in which to try these medications with patients can be quite challenging. In The Great Debate, held…
Through the development of a multidisciplinary musculoskeletal institute, we have created a model that facilitates coordination of care of complex patients between medical and surgical subspecialists, physical therapists, dieticians and social workers. A case is presented to demonstrate the improved care experience for both patients and providers and to share our learnings more broadly. The…
Interventions targeted at mitigating the risk of preeclampsia may reduce preterm birth and cesarean delivery in women with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and psoriasis. That’s one key finding of a retrospective study published in Arthritis Care & Research.1 The study set out to quantify the mediated effects of autoimmune conditions on adverse…
Investigators are tackling rheumatology practice challenges, assessing what drives career choices in pediatric rheumatology, improving fellowship training and more—all with the support of the Rheumatology Research Foundation.
Neutrophils, often hailed as guardians against infections, are maligned when it comes to rheumatoid arthritis (RA) due to their role in both the initial stage and disease progression. A new multicenter work, “A Neutrophil Activation Biomarker Panel in Prognosis and Monitoring of Patients with Rheumatoid Arthritis,” seeks to expand the literature on this topic.1 The…
Cardiovascular disease (CVD) is a leading cause of death in patients with rheumatoid arthritis (RA). Patients with RA have a 1.5 times increased risk for heart attack compared with the general population. Although the treatment of RA has advanced significantly, the ability to prevent cardiovascular events hasn’t followed. A study in Arthritis Care & Research…
In early 2021, Lindsey A. Criswell, MD, MPH, DSc, one of rheumatology’s preeminent autoimmune genetics researchers, will become the new director of the National Institute of Arthritis and Musculoskeletal and Skin Diseases. She will be the first woman to hold that post. Dr. Criswell will be leaving her current position as vice chancellor of research…
The FDA is recommending pregnant women avoid using NSAIDs as early as week 20 of pregnancy due to the risk of kidney problems in a developing fetus.
The SELECT-EARLY MTX-controlled trial examined the safety and efficacy of upadacitinib, a potent, reversible jakinib, as monotherapy in patients with moderately to highly active RA and poor prognostic features who are either naive for or have limited exposure to methotrexate.